
| | |
|--------------------------|---|
| Product name: | Kininogen 1 (13J10) Rabbit Monoclonal Antibody |
| Cat number: | MABN13024 |
| Conjugate: | Unconjugated |
| Size: | 100µL |
| Clone: | Monoclonal |
| Concentration: | 1mg/ml |
| Host: | Rabbit |
| Isotype: | IgG |
| Immunogen: | A synthetic peptide of human Kininogen 1 |
| Reactivity: | Human |
| Applications: | WB 1:2000-1:20000,IHC 1:100-1:200,IP 1:10-1:100,IF-P 1:100-1:200 |
| Molecular Weight: | 72kDa |
| Purification: | Affinity purification |
| Form: | Liquid |
| Buffer: | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% New type preservative N and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle. |
| Storage: | Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles. |
| Background: | (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (1) Kininogens are inhibitors of thiol proteases; (2) HMW- kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. |